RepliCel Life Sciences (REPCF) Ratios

22 Followers

RepliCel Life Sciences Ratios

REPCF's free cash flow for Q4 2025 was C$0.00. For the 2025 fiscal year, REPCF's free cash flow was decreased by C$ and operating cash flow was C$1.16. See a summary of the company’s cash flow.

Ratios	TTM	Mar 26	Dec 24	Mar 24	Mar 23
Liquidity Ratios
Current Ratio	―	0.02	0.04	0.09	0.31
Quick Ratio	―	0.02	0.04	0.09	0.31
Cash Ratio	―	<0.01	<0.01	0.03	0.20
Solvency Ratio	―	-0.08	-0.02	-0.06	-0.11
Operating Cash Flow Ratio	―	-0.15	-0.33	-0.78	-0.68
Short-Term Operating Cash Flow Coverage	―	-0.29	-0.86	-1.74	0.00
Net Current Asset Value	C$ ―	C$ -4.96M	C$ -4.60M	C$ -4.66M	C$ -6.08M
Leverage Ratios
Debt-to-Assets Ratio	―	10.53	4.63	3.03	0.05
Debt-to-Equity Ratio	―	-0.21	-0.15	-0.19	>-0.01
Debt-to-Capital Ratio	―	-0.26	-0.18	-0.24	>-0.01
Long-Term Debt-to-Capital Ratio	―	0.00	-0.01	-0.01	>-0.01
Financial Leverage Ratio	―	-0.02	-0.03	-0.06	-0.13
Debt Service Coverage Ratio	―	0.22	-0.49	-1.44	-109.83
Interest Coverage Ratio	―	5.82	-3.16	-9.30	-207.88
Debt to Market Cap	―	106.37	7.61	2.47	0.16
Interest Debt Per Share	―	0.02	0.01	0.02	<0.01
Net Debt to EBITDA	―	4.27	-1.89	-0.59	0.51
Profitability Margins
Gross Profit Margin	―	0.00%	100.00%	99.58%	100.00%
EBIT Margin	―	67.29%	-101.77%	-391.82%	-208.35%
EBITDA Margin	―	67.29%	-101.62%	-391.54%	-208.07%
Operating Profit Margin	―	67.29%	-101.77%	-391.82%	-393.80%
Pretax Profit Margin	―	-69.89%	-27.50%	-88.20%	-210.04%
Net Profit Margin	―	-113.63%	-27.50%	-88.20%	-210.04%
Continuous Operations Profit Margin	―	-69.89%	-27.50%	-88.20%	-210.04%
Net Income Per EBT	―	162.58%	100.00%	100.00%	100.00%
EBT Per EBIT	―	-103.86%	27.03%	22.51%	53.34%
Return on Assets (ROA)	―	-414.02%	-66.14%	-108.41%	-93.08%
Return on Equity (ROE)	―	8.18%	2.16%	6.89%	12.56%
Return on Capital Employed (ROCE)	―	-13.10%	24.37%	90.32%	109.29%
Return on Invested Capital (ROIC)	―	-29.95%	41.96%	192.12%	109.29%
Return on Tangible Assets	―	-414.02%	-66.14%	-108.41%	-93.08%
Earnings Yield	―	-4181.14%	-108.62%	-88.40%	-282.64%
Efficiency Ratios
Receivables Turnover	―	9.41	10.00	10.00	10.00
Payables Turnover	―	0.00	0.00	<0.01	0.00
Inventory Turnover	―	0.00	0.00	0.00	0.00
Fixed Asset Turnover	―	0.00	830.37	365.81	145.09
Asset Turnover	―	3.64	2.40	1.23	0.44
Working Capital Turnover Ratio	―	-0.21	-0.22	-0.23	-0.26
Cash Conversion Cycle	―	38.77	36.50	-77.84K	36.50
Days of Sales Outstanding	―	38.77	36.50	36.50	36.50
Days of Inventory Outstanding	―	0.00	0.00	0.00	0.00
Days of Payables Outstanding	―	0.00	0.00	77.88K	0.00
Operating Cycle	―	38.77	36.50	36.50	36.50
Cash Flow Ratios
Operating Cash Flow Per Share	―	>-0.01	>-0.01	-0.02	-0.04
Free Cash Flow Per Share	―	>-0.01	>-0.01	-0.02	-0.04
CapEx Per Share	―	<0.01	0.00	0.00	0.00
Free Cash Flow to Operating Cash Flow	―	1.00	1.00	1.00	1.00
Dividend Paid and CapEx Coverage Ratio	―	-71.86K	0.00	0.00	0.00
Capital Expenditure Coverage Ratio	―	-71.86K	0.00	0.00	0.00
Operating Cash Flow Coverage Ratio	―	-0.29	-0.78	-1.62	-34.41
Operating Cash Flow to Sales Ratio	―	-0.84	-1.50	-4.00	-3.98
Free Cash Flow Yield	―	-3082.31%	-592.65%	-400.66%	-536.16%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-0.02	-0.92	-1.13	-0.35
Price-to-Sales (P/S) Ratio	―	0.03	0.25	1.00	0.74
Price-to-Book (P/B) Ratio	―	>-0.01	-0.02	-0.08	-0.04
Price-to-Free Cash Flow (P/FCF) Ratio	―	-0.03	-0.17	-0.25	-0.19
Price-to-Operating Cash Flow Ratio	―	-0.03	-0.17	-0.25	-0.19
Price-to-Earnings Growth (PEG) Ratio	―	>-0.01	0.01	0.02	<0.01
Price-to-Fair Value	―	>-0.01	-0.02	-0.08	-0.04
Enterprise Value Multiple	―	4.31	-2.14	-0.84	0.15
Enterprise Value	―	1.03M	769.35K	1.17M	-109.19K
EV to EBITDA	―	4.31	-2.14	-0.84	0.15
EV to Sales	―	2.90	2.17	3.30	-0.31
EV to Free Cash Flow	―	-3.46	-1.45	-0.83	0.08
EV to Operating Cash Flow	―	-3.46	-1.45	-0.83	0.08
Tangible Book Value Per Share	―	-0.07	-0.07	-0.08	-0.16
Shareholders’ Equity Per Share	―	-0.07	-0.07	-0.08	-0.16
Tax and Other Ratios
Effective Tax Rate	―	0.00	0.00	0.00	0.00
Revenue Per Share	―	<0.01	<0.01	<0.01	<0.01
Net Income Per Share	―	>-0.01	>-0.01	>-0.01	-0.02
Tax Burden	―	1.63	1.00	1.00	1.00
Interest Burden	―	-1.04	0.27	0.23	1.01
Research & Development to Revenue	―	0.00	0.32	1.49	1.76
SG&A to Revenue	―	0.33	1.70	3.43	3.18
Stock-Based Compensation to Revenue	―	0.00	0.09	0.68	0.20
Income Quality	―	1.20	5.46	4.54	1.90

Currency in CAD